Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZNF232 antisense RNA 1 (ZNF232-AS1)
- Target
- ZNF232-AS1
- Molecular classification
- Antisense RNA, Long noncoding RNA (lncRNA), Noncoding RNA, Other (does not belong to protein-coding/receptor/enzyme/transcription factor families)
01
Overview
ZNF232 antisense RNA 1 (ZNF232-AS1) is a long noncoding RNA transcribed antisense to the ZNF232 gene (zinc finger protein 232), a DNA-binding transcription factor. ZNF232-AS1 itself does not code for a protein but may regulate the expression of ZNF232 through epigenetic, transcriptional, or post-transcriptional mechanisms typical of antisense lncRNAs. It has no established function in normal biology or disease, but recent studies suggest its expression may be altered in cancers like hepatocellular carcinoma, where it could serve as a novel biomarker for prognosis. Currently, there is no evidence of it being a drug target, and there are no known drugs that interact specifically with ZNF232-AS1[5][7][9].
- Other names
- ZNF232-AS1
02
Mechanism of action
Not applicable. No drugs targeting ZNF232-AS1 with described mechanisms of action.
03
Biological functions
Regulation of gene expressionPossible epigenetic and post-transcriptional modulation of its sense gene (ZNF232)Roles of antisense lncRNAs generally include influencing transcription, mRNA stability, translation, and chromatin modification, but the specific function of ZNF232-AS1 is not experimentally characterized yet
04
Disease associations
Cancer (emerging evidence in hepatocellular carcinoma prognostics; further roles unknown)Most studies identify ZNF232-AS1 as a candidate prognostic marker in cancer models but do not define a direct functional or pathogenic mechanism
05
Biomarkers
Potential prognostic biomarker in hepatocellular carcinoma (HCC) patient stratificationZNF232-AS1 was highlighted in recent prognostic gene panels for HCC, though mechanistic or clinical biomarker validation is pending
Beyond the preview
Go deeper on ZNF232 antisense RNA 1 (ZNF232-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZNF232 antisense RNA 1 (ZNF232-AS1).